Scan Results
Daily timeframeMerck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. At a $56.89B market cap, Merck KGaA ranks as a large-cap company within healthcare. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments.
Market Cap
$56.89B
Beta
0.78
P/E (TTM)
22.44
P/E (Fwd)
15.06
EPS (TTM)
$5.83
EPS (Fwd)
$8.69
ROE
8.5%
ROA
4.7%
Cash
$3.77B
Total Debt
$12.04B
Free CF
$3.08B
52W Change
13.3%
Annual Financials
Cash vs Debt
The company holds $3.77B in cash, though total debt stands at $12.04B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $3.08B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 8.5%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.7% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $19.69B (2021) to $21.10B (2025).
Investors considering Merck KGaA should weigh the typical risks associated with MRK.DE's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Merck KGaA's trajectory.